source
- Roche bets up to $813M on Zymeworks’ lung cancer trispecific T cell engagerRoche will pay Zymeworks $55 million upfront plus another $40 million once the partnership asset enters Phase 1b development and up to $718 million in additional milestones.
- Swiss biotech Windward Bio files for Nasdaq IPO to raise funds for China-derived assets and R&DWindward Bio, a Basel-based European biotech founded two years ago, announced it has filed its registration statements to list on Nasdaq. The company plans to use the proceeds to support two clini…